Arix Bioscience
Arix Bioscience, a prominent player in the research and development services sector, is headquartered in Great Britain. Founded in 2016, the company has quickly established itself as a leader in the life sciences industry, focusing on the development of innovative therapies and technologies. Arix Bioscience operates primarily in the UK and Europe, leveraging its expertise to support early-stage biotechnology companies.
The firm is renowned for its unique approach to investment and development, providing not only capital but also strategic guidance to its portfolio companies. Arix's commitment to advancing healthcare solutions has positioned it as a key contributor to the biotech landscape, with notable achievements in fostering groundbreaking research. Through its dedication to innovation, Arix Bioscience continues to shape the future of medical science.
-3 vs industry average
Arix Bioscience’s score of 26 is lower than 47% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Arix Bioscience?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
Arix Bioscience's reported carbon emissions
Arix Bioscience, a research and development services company based in GB, is committed to achieving Net-Zero operations by 2050 or sooner, aiming to eliminate over 90% of its emissions. While specific emissions reduction targets for the company are not detailed, they have reported emissions across Scope 1, 2, and 3. In 2022, Arix Bioscience reported a total of approximately 13,290 kg CO2e. This comprised of about 3,680 kg CO2e for Scope 1, and approximately 4,410 kg CO2e for Scope 2 (market-based). Scope 3 emissions for 2022 were about 5,210 kg CO2e. For 2021, the company's total emissions were approximately 12,030 kg CO2e. This included roughly 4,860 kg CO2e for Scope 1 and about 2,670 kg CO2e for Scope 2 (market-based). Scope 3 emissions in 2021 totalled approximately 2,900 kg CO2e. In 2020, Arix Bioscience's emissions included approximately 5,020 kg CO2e for Scope 1 and around 5
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Arix Bioscience’s Climate Goals (2030 & 2050)
2 goals2050
90% reduction in all scopes
Target Two: Known as our ‘long-term target’, we need to operate as a fully Net-Zero business by 2050 or sooner. This involves removing more…
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Arix Bioscience
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project